Illinois Ventures portfolio company REVOLUTIONS Medicines announced the close of a $100M C round to continue their work in novel therapies addressing frontier targets in RAS-dependent cancers. REVOLUTION Medicines is a leader in the discovery and development of precise small molecule therapeutics designed to translate frontier oncology targets within notorious pathways to outsmart cancer. Proceeds will support the continued advancement of the company’s pipeline, which includes programs addressing elusive targets within the RAS pathway such as KRASG12C(GTP) and other specific tumorigenic mutants of RAS.
“Our position at the forefront of RAS pathway-focused therapeutics development is powered by a deep commitment to RAS pathway biology and our differentiated drug discovery capabilities,” noted REVOLUTION Medicines president and CEO, Mark Goldsmith. “Our innovation engine enables the creation of sophisticated drug candidates that inhibit protein targets that defy conventional drug discovery methods, which we believe will bring the promise of targeted therapy to inadequately served cancer patients.”
To learn more about REVOLUTION Medicines, click here.